These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 26547803)
1. ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making. von Laffert M; Stenzinger A; Hummel M; Weichert W; Lenze D; Warth A; Penzel R; Herbst H; Kellner U; Jurmeister P; Schirmacher P; Dietel M; Klauschen F Lung Cancer; 2015 Dec; 90(3):465-71. PubMed ID: 26547803 [TBL] [Abstract][Full Text] [Related]
2. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200 [TBL] [Abstract][Full Text] [Related]
3. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130 [TBL] [Abstract][Full Text] [Related]
4. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. von Laffert M; Warth A; Penzel R; Schirmacher P; Kerr KM; Elmberger G; Schildhaus HU; Büttner R; Lopez-Rios F; Reu S; Kirchner T; Pauwels P; Specht K; Drecoll E; Höfler H; Aust D; Baretton G; Bubendorf L; Stallmann S; Fisseler-Eckhoff A; Soltermann A; Tischler V; Moch H; Penault-Llorca F; Hager H; Schäper F; Lenze D; Hummel M; Dietel M J Thorac Oncol; 2014 Nov; 9(11):1685-92. PubMed ID: 25436802 [TBL] [Abstract][Full Text] [Related]
5. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. Minca EC; Portier BP; Wang Z; Lanigan C; Farver CF; Feng Y; Ma PC; Arrossi VA; Pennell NA; Tubbs RR J Mol Diagn; 2013 May; 15(3):341-6. PubMed ID: 23499337 [TBL] [Abstract][Full Text] [Related]
6. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC). Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969 [TBL] [Abstract][Full Text] [Related]
7. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Savic S; Diebold J; Zimmermann AK; Jochum W; Baschiera B; Grieshaber S; Tornillo L; Bisig B; Kerr K; Bubendorf L Lung Cancer; 2015 Aug; 89(2):104-9. PubMed ID: 26056079 [TBL] [Abstract][Full Text] [Related]
8. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247 [TBL] [Abstract][Full Text] [Related]
9. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches. Demidova I; Grinevich V; Avdalian A; Imyanitov E; Gikalo M; Savelov N; Novikova I; Samuilenkova O; Tiurin V; Ulianova E; Tsimafeyeu I; Tjulandin S Lung Cancer; 2017 Jan; 103():17-23. PubMed ID: 28024691 [TBL] [Abstract][Full Text] [Related]
10. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material. Minca EC; Lanigan CP; Reynolds JP; Wang Z; Ma PC; Cicenia J; Almeida FA; Pennell NA; Tubbs RR J Thorac Oncol; 2014 Apr; 9(4):464-8. PubMed ID: 24736067 [TBL] [Abstract][Full Text] [Related]
11. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803 [TBL] [Abstract][Full Text] [Related]
12. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance. Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405 [TBL] [Abstract][Full Text] [Related]
13. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695 [TBL] [Abstract][Full Text] [Related]
15. Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing. Selinger C; Cooper W; Lum T; McNeil C; Morey A; Waring P; Amanuel B; Millward M; Peverall J; Van Vliet C; Christie M; Tran Y; Diakos C; Pavlakis N; Gill AJ; O'Toole S Histopathology; 2015 Nov; 67(5):654-63. PubMed ID: 25847523 [TBL] [Abstract][Full Text] [Related]
16. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552 [TBL] [Abstract][Full Text] [Related]
17. Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC). Kotoula V; Bobos M; Vassilakopoulou M; Tsolaki E; Chrisafi S; Psyrri A; Lazaridis G; Papadopoulou K; Efstratiou I; Michail-Strantzia C; Debelenko LV; Kosmidis P; Fountzilas G Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):60-70. PubMed ID: 25153496 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275 [TBL] [Abstract][Full Text] [Related]
19. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization. Wang W; Tang Y; Li J; Jiang L; Jiang Y; Su X Cancer Cytopathol; 2015 Feb; 123(2):117-22. PubMed ID: 25529354 [TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples. Abe H; Kawahara A; Azuma K; Taira T; Takase Y; Fukumitsu C; Murata K; Yamaguchi T; Akiba J; Ishii H; Okamoto I; Hoshino T; Takamori S; Kage M J Thorac Oncol; 2015 May; 10(5):800-805. PubMed ID: 25898958 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]